LeMaitre Vascular (NASDAQ:LMAT) Releases Q4 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its fourth quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.640-0.690 for the period, compared to the consensus earnings per share estimate of 0.630. The company issued revenue guidance of $61.8 million-$63.8 million, compared to the consensus revenue estimate of $64.3 million. LeMaitre Vascular also updated its FY 2025 guidance to 2.480-2.530 EPS.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald increased their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Barrington Research reissued an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Roth Capital reissued a “buy” rating and set a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and a consensus price target of $100.60.

LeMaitre Vascular Trading Up 2.0%

LMAT stock traded up $1.72 during mid-day trading on Friday, reaching $87.32. The company had a trading volume of 111,049 shares, compared to its average volume of 181,590. The company has a market capitalization of $1.98 billion, a PE ratio of 42.39, a price-to-earnings-growth ratio of 2.29 and a beta of 0.77. The firm has a 50 day moving average of $89.75 and a 200 day moving average of $87.00. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm had revenue of $61.05 million during the quarter, compared to the consensus estimate of $62.18 million. During the same quarter in the previous year, the company posted $0.49 earnings per share. The company’s revenue was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. On average, equities analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 4th. Investors of record on Thursday, November 20th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, November 20th. LeMaitre Vascular’s payout ratio is presently 38.83%.

Insider Buying and Selling

In other news, Director John A. Roush sold 6,561 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the sale, the director directly owned 2,916 shares in the company, valued at $269,875.80. This represents a 69.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David B. Roberts sold 10,815 shares of the business’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the transaction, the director owned 17,976 shares in the company, valued at approximately $1,660,802.64. This represents a 37.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its stake in LeMaitre Vascular by 27.0% during the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after purchasing an additional 55,804 shares in the last quarter. Ameriprise Financial Inc. grew its position in LeMaitre Vascular by 14.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 231,282 shares of the medical instruments supplier’s stock valued at $19,208,000 after acquiring an additional 28,556 shares in the last quarter. Millennium Management LLC increased its stake in LeMaitre Vascular by 119.8% during the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares during the period. Qube Research & Technologies Ltd lifted its position in shares of LeMaitre Vascular by 7.0% during the second quarter. Qube Research & Technologies Ltd now owns 173,839 shares of the medical instruments supplier’s stock worth $14,437,000 after purchasing an additional 11,416 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of LeMaitre Vascular by 30.5% in the second quarter. Bank of America Corp DE now owns 115,263 shares of the medical instruments supplier’s stock valued at $9,573,000 after purchasing an additional 26,966 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.